

This work is licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0).
No permission to resale without signed publisher agreement.

Neuroendocrinology Letters Volume 38 No. 5 2017
ISSN: 0172-780X; ISSN-L: 0172-780X; Electronic/Online ISSN: 2354-4716
Web of Knowledge / Web of Science: Neuroendocrinol Lett
Pub Med / Medline: Neuro Endocrinol Lett

Novel insights in ultrasound evaluation of thyroid gland in children with papillary thyroid carcinoma

Dominika JANUŚ^{1,2}, Małgorzata WÓJCIK^{1,2}, Anna KALICKA-KASPERCZYK^{1,2}, Grażyna DRABIK³, Łukasz WYROBEK⁴, Anna WĘDRYCHOWICZ^{1,2}, Jerzy B. STARZYK^{1,2}

¹ Department of Pediatric and Adolescent Endocrinology, Chair of Pediatrics, Institute of Pediatrics, Jagiellonian University Medical College, Krakow, Poland

² Department of Pediatric and Adolescent Endocrinology, University Children Hospital in Krakow, Poland

³ Department of Clinical Immunology and Transplantation, Institute of Pediatrics, Jagiellonian University, Medical College, Krakow, Poland.

⁴ University Children Hospital, Department of Radiology, Krakow, Poland

Correspondence to: Dominika Januś, MD., PhD.
Department of Pediatric and Adolescent Endocrinology, Chair of Pediatrics
Institute of Pediatrics, Jagiellonian University Medical College
Wielicka St. 265, 30-663 Krakow, Poland.
TEL: +48 12 658 12 77; FAX: +48 12 658 10 05; E-MAIL: dominika.janus@uj.edu.pl

Submitted: 2017-05-15 *Accepted:* 2017-09-15 *Published online:* 2017-10-18

Key words: **autoimmune thyroiditis; papillary thyroid carcinoma; papillary thyroid microcarcinoma; ultrasonography of thyroid gland; normoechoogenic thyroid**

Neuroendocrinol Lett 2017; **38**(5):367–374 PMID: 29106792 NEL380517A07 ©2017 Neuroendocrinology Letters • www.nel.edu

Abstract

BACKGROUND: The coincidence of autoimmune thyroiditis (AIT) in patients with papillary thyroid carcinoma (PTC) is ranging between 10 and 58% in the general population.

MATERIAL AND METHODS: In the present study retrospective ultrasound, clinical and autoimmune assessment of 24 patients diagnosed with papillary thyroid carcinoma between 2000–2016 was performed.

RESULTS: The coexistence of PTC and AIT was found in 50% of patients with PTC. Patients were divided into two groups. PTC AIT (+) group involved 12 children at the mean age 14.9 years (range 11–20 years, 9 girls) and PTC AIT (–) 12 children at the mean age 12.9 years (range 7–18 years, 5 girls). Papillary thyroid microcarcinoma (PTMC) was diagnosed in 6 patients (in 5 with AIT). US characteristics of PTC was heterogenous: hypoechogenic with/without increased vascularisation, normoechoogenic with halo, with/without microcalcifications. In 70% PTC AIT (+) and in all PTC AIT (–) patients ultrasound analysis revealed that the thyroid tissue of the whole gland was normoechoogenic. Local metastases in lymph nodes were found in 40% of PTMC AIT (+).

CONCLUSION: Lack of increased vascularization and microcalcifications and presence of `halo` in the nodule does not exclude malignancy. Due to the presence of lymph node involvement in PTMC in all children with PTC total thyroidectomy should be performed with lymph nodes verification.

Abbreviations:

DTC - differentiated thyroid carcinoma
PTC - papillary thyroid carcinoma
PTMC - papillary thyroid microcarcinoma
AIT - autoimmune thyroiditis

AITD - autoimmune thyroid disease
FNAB - fine needle aspiration biopsy
aTPO - thyroperoxidase antibody
aTG - thyroglobulin antibody
TRab - TSH receptor antibody

INTRODUCTION

Autoimmune thyroid disease (AITD) is the most common cause of acquired thyroid disease in pediatric patients (Zdraveska & Kocova 2012). The frequency of AITD is rising and has been reported between 0.3–2% in children and 4–9.6% in adolescents (Zois *et al.* 2003). Papillary thyroid carcinoma (PTC) accounts for 90% or more of all childhood differentiated thyroid carcinoma (DTC) cases (Niedziela *et al.* 2016). The prevalence of PTC, especially papillary thyroid microcarcinoma (PTMC) is rising in the last years partly due to more frequent ultrasound (US) assessments and US controlled fine needle aspiration biopsy (FNAB) of small nodules of the thyroid gland.

In the first report on the coincidence of thyroid cancer and AIT Dailey *et al.* (1955) postulated that AIT might be considered a precancerous lesion. Other researchers reported a coincidence of AIT in PTC ranging from 10–58% in the general population (Ott *et al.* 1985; Carson *et al.* 1996; Schaffler *et al.* 1998; Niedziela *et al.* 2006; Jankovic *et al.* 2013). In pediatric patients with DTC the coincidence of AIT is ranging from 6.3–43% depending on the patients selection (Danese *et al.* 1997; Corrias *et al.* 2008; O’Groman *et al.* 2010; Park *et al.* 2013; Iliadou *et al.* 2015). In a large case series presented by Corrias *et al.* (2008) thyroid nodules were found in 115 of 365 patients with AIT (31.5%), with 11/115 cases of PTC (9.6%). In a large study including 108 children Iliadou *et al.* (2015) have found that 28.6% of the patients with DTC (in 93.5 % with PTC) presented AIT.

In the last years there is an increase of coincidence of AIT and PTC. In adult patients with PTC, the prevalence of chronic lymphocytic thyroiditis increased four-fold in men and two-fold in women between 1999 and 2008 (Oh *et al.* 2014). In pediatric patients with PTC Niedziela *et al.* (2015) found that the prevalence of chronic lymphocytic thyroiditis increased ten-fold between 1996–2000 and 2001–2015 years.

According to the current pediatric guidelines neck US should be performed at least every 12 months in children with autoimmune thyroid disease (Niedziela *et al.* 2016).

The aim of the present study is ultrasound, clinical and autoimmune characterization of patients with papillary thyroid carcinoma.

SUBJECTS AND METHODS

Subjects

Retrospective analysis of medical records and thyroid ultrasound results of 24 patients diagnosed with PTC between 2000 and 2016 in the major tertiary pediatric endocrinology center was performed. The analysis included age at diagnosis, gender, the cause of referral to the endocrinologist, thyroid status (euthyroid, hypothyroid, hyperthyroid), levels of autoantibodies (aTPO assessed in 24 patients, aTG in 5 patients, TRab

in 3 patients) and ultrasound features of the malignant nodule and the thyroid gland surrounding the nodule.

Postoperative staging was done based on the tumour, nodes and metastases (TNM) system proposed by the American Joint Committee on Cancer (Ito *et al.* 2010).

Patients were divided into two groups. PTC AIT (+) group involved 12 children at the mean age 14.9 years (range 11–20 years, 9 girls). PTC AIT (–) group involved 12 children at the mean age 12.9 years (range 7–18 years, 5 girls).

Methods

AITD was diagnosed based on clinical (presence of goiter, firm consistency of the thyroid gland), hormonal (hypothyroidism or thyrotoxicosis), typical features of chronic autoimmune thyroiditis on thyroid ultrasound assessment and increased aTPO, and/or aTG and/or TRab antibodies levels. AIT was diagnosed in euthyroid patients with an increased aTPO and/or aTG and/or TRab antibodies levels. PTMC was diagnosed after FNAB fulfilling Bethesda criteria (Cibas *et al.* 2009), and if on US assessment its diameter was ≤ 10 mm. In patients with PTC total thyroidectomy with lateral and central lymph nodes histopathological verification was performed.

The study was approved by the Institutional Review Board.

RESULTS

From 2000 to 2016 we had the total number of 24 cases of PTC in children treated in our center (Table 1). In the last two years an increase of newly diagnosed small PTC of diameter below 10 mm was observed, that may be associated with more frequent ultrasound assessment of patients in this time period, every 6 to 12 months (Table 1).

The coexistence of PTC with AIT was found in 50% (12/24) of patients and there was also an increase in the last two years (Table 1). In two patients: one AIT (+) and one AIT (–) PTC developed 7 and 13 years after prophylactic central nervous system irradiation due to acute lymphoblastic leukemia and in one patient AIT (–) 9 years after chest irradiation due to Wilms’ tumor (Table 1). In patient 11 PTC AIT (+) diabetes mellitus type 1 was diagnosed 5 years prior to PTC.

Thyroid status analysis of patients with PTC and AIT (+) at presentation found that 1 patient presented with thyrotoxicosis, 5 with subclinical (compensated hypothyroiditis) and 6 were euthyroid. 11 patients with PTC AIT (–) were euthyroid and 1 presented with compensated hypothyreosis (Table 1).

Analysis of the whole group of 24 PTC revealed that patients with PTC AIT (+) when compared to patients with PTC AIT (–) were older (14.9 vs 12.9 years, ns), females predominated (75% vs 41.6%), 5 micro PTC (41.6%) were detected (mean diameter 8.4 mm) vs. 1 microPTC in AIT (–) patients, the lymph node

Tab. 1. Clinical characterisation of patients.

	Age yrs	Cause of referral	Thyroid US PTC(mm)	TNM	PTC variant	131 J therapy	aTPO IU/ml N<30	aTG U/ml N<30	TRAb IU/l N<1	TSH uIU/ml N:0.4-4.0	ft3 pmol/l N:3.6-8.6	ft4 pmol/l N:10-25
AIT (+)												
1	12	Goiter	20	PT1bN1bM0	follicular	+	70.7			2.41	7.06	18
2	20	US	10	PT1aN1bM0 7 years after prophylactic brain irradiation	classic	+	722.5			0.64	5.72	12.9
3	14	Goiter	15x20	PT1bN1bM0	follicular	+	1828			4.71		13.1
4	13	Goiter	31x39	PT2N1bM1	classic	+	726.6			3.21	5.4	17.2
5	18	Goiter	13	pT1bN0M0	classic	+	<30	<20	5.2	0.02	13.4	31.6
6	17	US	21x16x26	PT2N1bM0	follicular	+	853.4		0.7	1.02		16.9
7	13	Lymph node enlargement	23	PT3N1bM1	diffuse sclerosing	+	>9000	>8000	1.2	4.12	5.4	10.6
8	13	Goiter	8x8x9	PT1aN1aM0	classic /follicular	+	126.2	154.3		5.05	7.1	20.2
9	14	USG	7 and 2	PT1aN0M0	7 mm-classic/ solid 2 mm-follicular	-	1300			4.8		1.18
10	16	Goiter	6	PT1aN0M0	classic	-	5911.2	300		2.12		15.5
11	17	USG	10	pT1aN0M0	classic	-	1271.7			5.01		11.4
12	11	Goiter	12	pT1bN0M0	follicular with capsule	-	42.94	43.39		2.01		1.31
AIT (-)												
13	7	Goiter	30	PT2N1bM0	classic/diffuse sclerosing/ solid/ clear cell /follicular	+	11.6			1.83	6.9	12.2
14	16	USG	n.a.	PT1bN1bM0 13 years after prophylactic brain irradiation	classic	+	-			1.44		
15	16	Goiter	17	PT2N0Mx	classic	+	-			2.4		13.4
16	18	Goiter	12x18	PT1bN1bM0	follicular	+	-			3.44	4.7	9.56
17	14	Lymph nodes enlargement	15x25	PT2N1bM0 9 years after chest irradiation due to Wilms tu	follicular	+	15.7			2.05	4.8	19.2
18	17	Goiter	20x20	PT1bN1bM0	follicular	+	26.2			2.1	5.8	17.2
19	7	Goiter	13x11.5x21	PT2N1bM0	diffuse sclerosing	+	17.2			4.28	6.4	13.7
20	12	Lymph nodes enlargement	60x40	PT3N1bMx	classic	+	15.1			2.6		15.2
21	14	Goiter	12x13.1x17.6	PT1bN1bMx	classic / follicular	+	-			3.03	5.79	11.4
22	10	Lymph nodes enlargement	40	PT3N1bMx	solid with focus of anaplastic dedifferentiation	+	-			0.6	3.9	16.3
23	15	USG	13x7	PT1bN1bM0	classic	+	<30	<20		1.7	4.1	1.03
24	9	Goiter	8x7.5x11	PT1bN0M0	follicular	-	<5.5	27.7	-	2.9	5.8	15.5

involvement reached 58.3% (vs 91.6%), mean TSH (after excluding a patient with thyrotoxicosis at presentation) was higher (3.2 vs 2.3 uIU/ml). The cause of referral to the endocrinologist in PTC AIT (+) was a goiter in 7/12 (58.3%), a nodule found on ultrasound in 4/12 (33.3%) and in 1 patient lymph nodes enlargement (8.3%). In PTC AIT (-) the cause of referral was also

a goiter in 7/12 (58.3%) patients, in 3/12 (25%) lymph nodes enlargement and a nodule found on US in 2/12 (16.7%). Three patients were referred to the hematology unit first because of lymphadenopathy at presentation and the suspicion of Hodgkin lymphoma.

In patients with PTC AIT (+) the mean aTPO level assessed in 12 patients was 1823.6 IU/ml (range from

<30 to >9000), mean aTG assessed in 5 patients was 1703.5 U/ml (range <20 to >8000) and TRAb level assessed in 3 patients was 2.4 IU/l (range 0.7–5.2). The highest unmeasurable levels of aTPO >9000 IU/ml and aTG >8000 U/ml were found in a patient with diffuse sclerosing variant of PTC (Table 1).

In PTC AIT (+) we have been able to retrospectively assess thyroid ultrasound images of 10 out of 12 patients (83.3%). In 7/10 (70%) hypoechoogenic PTC lesions were found (patients: 2,4,5,6,8,9,10), in 2/10 normoechoogenic with hypoechoogenic ‘halo’ (patients: 11,12) and in 1 patient with diffuse sclerosing PTC variant disseminated hyperechoogenic lesions in the whole thyroid gland were found (patient 7). In 7/10 images no microcalcifications were visible on ultrasound images (2,6,10,8,9,11,12) and in 2/10 no increased vascularisation of the nodule was seen (patients: 8,9) (Figure 1).

In PTC AIT (-) patients we have been able to assess thyroid ultrasound images of 8 out of 12 patients (66.7%). In 4/8 irregular hypoechoogenic PTC lesions with microcalcifications were found (patients: 13,18,20,21), in 2/8 normo/hypoechoogenic with hypoechoogenic ‘halo’ without microcalcifications (patients: 16,24) and in 1/8 hypoechoogenic without microcalcifications (patient: 23). In patient 19 diffuse sclerosing PTC variant was confirmed after histopathology. In all except one lesion

increased vascularisation was found (patient 23). In patient 22 CT scan was performed due to neck lymph node enlargement and Hodgkin lymphoma suspicion, histopathology of lymph node revealed PTC (Figure 2).

To summarise in 15/18 (83.3%) patients malignant nodule was found to be hypoechoogenic on ultrasound imaging.

In 7/10 (70%) AIT (+) patients (2,6,8–12) ultrasound analysis revealed that the thyroid tissue of the whole gland was normoechoogenic and in 4/7 of these patients (8,9,11,12) the thyroid tissue directly surrounding the PTC nodules (with diameter from 7 to 12 mm) was hyperechoogenic forming like a ‘border’ limiting the cancer (Figure 1).

In all PTC AIT (-) patients thyroid tissue of the whole gland outside the PTC nodule was normoechoogenic. In the majority of patients PTC lesion was invasive and the diameter was larger than in PTC AIT (+) (24.8 vs 15.9 mm, $p < 0.09$).

In our series of patients uninodularity was more frequent than multinodularity (patient 9).

PTC was suspected after first FNAB in 16/24 (66.7%) patients (1,3,5,6,8,9,11,13,14,16,17,18,19,20,21,23). PTC was suspected after second FNAB in one patient (4, 4.2%). PTC was suspected after third FNAB in two patients (2,24;8.3%).




Fig. 1. Ultrasound features of PTC in AIT(+) patients.




Fig. 2. Ultrasound features of PTC in AIT(-) patients.




Fig. 3. Histopathology of PTMC in patient 9 AIT (+). The nodule and its border: 3A-HE×15-the nodule surrounded by a border, 3B-HE×40-the border, 3C-HE×40-the border. PTMC variants found in patient 9: 3D-solid, 3E-classic, 3C-follicular.

PTC was found after histopathological evaluation of removed thyroid gland in patients: 10 and 12 (8.3%). In patient 10 total thyroidectomy was performed due to large goiter (volume 55 ml) causing dyspnea and multinodularity (FNAB was benign twice). In patient 12 FNAB was benign twice, total thyroidectomy was performed due to multinodularity and increased diameter of nodules.

PTC was found in removed lymph node due to Hodgkin lymphoma suspicion in patients: 7,15,22 (12.5%).

Following PTC variants were found: 13/24 (54.2%) – classic (in 3 patients also with other components: diffuse sclerosing, solid, clear cell, follicular), 8/24 (33.3%) – follicular, 2/24 (8.3%) diffuse sclerosing and 1 patient – solid with anaplastic dedifferentiation (Table 1). Histopathology revealed that above mentioned hyperechoic border of PTMC seen on ultrasound was formed by fibrotic tissue, microcalcifications and foci of lymphocytic infiltration (patients 8,9,11,12) (Figure 3).

In PTC AIT (+) patients local metastases in neck lymph nodes were found in 7/12 patients (58.3%), in

two also in the lungs and mediastinum. In 2/5 PTMC (40%) metastases in lymph nodes were found including one patient with microPTC of 9 x 8 x 8 mm dimensions with metastases found in as many as in 13/29 of lymph nodes assessed. In PTC AIT (-) patients local metastases in lymph nodes were found in 11/12 (91.7%).

Three patients PTC AIT (+) PT1aN0M0 (patients 9,10,11) and one patient PTC AIT (-) PT1bN0M0 (patient 24) were not treated with ¹³¹I therapy.

DISCUSSION

In this study, we presented the clinical and ultrasound characteristics of 24 pediatric patients with PTC with or without coincidence of autoimmune thyroiditis. The main cause of referral to the endocrinologist was a goiter in both groups. In 50% of patients autoimmune thyroiditis was diagnosed on the basis of a presence of an increased aTPO, aTG or TRab levels in serum. No PTC AIT (+) patient presented with an overt hypothyroiditis, 50% were euthyroid and in 50% AITD was diagnosed (41.7% presented with compensated hypothyroiditis and one with hyperthyroiditis). Ultrasound analysis of the thyroid gland provided further useful diagnostic information. Among patients with thyroid cancer, hypoechogenic malignant nodules predominated (83%) over other ultrasound patterns. Whereas typically in AIT or AITD ultrasound imaging reveals hypoechogenic thyroid gland due to more or less advanced lymphocytic infiltration that can be diffuse or focal, in our PTC cohort we observed that on ultrasound imaging inflammatory process in patients with PTC was not very advanced (Januś *et al.* 2017). In 70% PTC AIT (+) patients ultrasound analysis revealed that the thyroid tissue of the whole gland was normoechogenic and in 57.1% of these cases the thyroid tissue directly surrounding the PTC nodule was hyperechogenic forming like a 'capsule/border' limiting the cancer. Histologically, in above mentioned cases, fibrosis, microcalcifications and foci of lymphocytic infiltration were found in this tissue. The question arises then if in these patients autoimmune thyroiditis is not secondary to the cancer. These data are supported by Paparodis *et al.* (2014) reports that the form of AITD pathology (destructive with clinically overt hypothyroiditis vs. a less-destructive with clinically compensated hypothyroiditis or euthyroid) may play a role in differentiated thyroid cancer risk. Patients with less destructive AITD were described to have a higher risk for differentiated thyroid cancer than patients with destructive AITD (Paparodis *et al.* 2014). These observations could provide a support for the hypothesis that autoimmune thyroiditis might be a secondary event (Januś *et al.* 2017).

According to Noureldine *et al.* (2015), recognition of AITD as a precursor or a risk factor for thyroid cancer in pediatric population, would have a high clinical impact, given that Hashimoto's thyroiditis is not rare

and its incidence is rising in children (Ehlers & Schott 2014; Oh *et al.* 2014; Noureldine & Tufano 2015). It remains controversial whether autoimmune thyroiditis in children is a risk factor for developing PTC, is an incidental concurrent finding, or is a part of the host-tumor response system (Ehlers & Schott 2014; Noureldine & Tufano 2015).

Studies suggest that similar molecular mechanisms may influence early stages of oncogenesis and inflammation in the thyroid gland (Ehlers & Schott 2014; Noureldine & Tufano, 2015). As presented by Ehlers *et al.* (2014) TG and TPO represent the main target antigens for cellular cytotoxic as well as humoral immune reactions (Ehlers & Schott 2014; Noureldine & Tufano 2015). In addition to Paparodis *et al.* (2014) study presenting that elevated anti-TPO antibodies appear to protect against thyroid cancer in patients with HT we would like to highlight the diffuse sclerosing variant of PTC with local and distant metastases where we have found unmeasurable high values of both aTPO and aTG levels. As presented by Ehlers *et al.* (2014) tumor-protecting feature of TPO might be explained by (a) complement-mediated cell death, that is anti-TPO antibody-dependent because anti-Tg antibodies do not fix complement (Weetman 2004; Ehlers & Schott 2014), and (b) anti-TPO antibody-dependent cell toxicity due to the exclusive binding of anti-TPO antibodies to their effector cells via Fc-g receptor I (CD64) that is known to be expressed on monocytes (Rebuffat *et al.* 2008; Ehlers & Schott, 2014).

By contrast, aTG seem to represent a risk factor for PTC (Grani *et al.* 2013; Ehlers & Schott 2014; Vasileiadis *et al.* 2014). One reason for this effect could be the fact that aTG from PTC patients recognize different TG epitopes than do aTG from patients with autoimmune thyroid diseases (HT and Graves' disease) and from PTC patients with associated thyroiditis (Latrofa *et al.* 2008; Ehlers & Schott, 2014).

By analogy to autoimmune thyroiditis, TPO and TG also seem to represent the specific target antigens for the immune response in PTC (Ehlers & Schott 2014; Noureldine & Tufano 2015). Whether PTC develops despite autoimmunity or due to inflammation and preexisting autoimmunity, or whether AIT develops because of cross-reacting antitumor immunity, needs further research in pediatrics (Ehlers & Schott 2014).

From pathological perspective, it is important to distinguish between diffuse lymphocytic infiltration and focal peritumoral lymphocytic thyroiditis (Noureldine & Tufano, 2015). Hashimoto's thyroiditis is a diffuse lymphocytic infiltration; therefore, it is considered an independent chronic process and does not signify a reaction to the tumor (Ehlers & Schott 2014; Noureldine & Tufano 2015). The reactive alterations of stromal cells caused by the chronic inflammation may lead to cellular damage, thereby resulting in tumor development (Buyukasik *et al.* 2011; Noureldine & Tufano 2015). The reason for the induced antitumor immune

response might be the existence of yet undiagnosed papillary thyroid microcarcinomas (PTMC) (Ehlers & Schott 2014). In our study ultrasound imaging in 4 patients PTC AIT (+), 3 of them with PTMC, is in favour for the latter category of the infiltration taking into account that the thyroid was normoechogenic and the direct tissue surrounding the nodule was hyper-echogenic, 'limiting' the lesion, and could be a part of peritumoral lymphocytic infiltration with positive antibodies detected in serum. PTMC is considered as the earlier stage of disease which eventually evolves into PTC, potentially triggered by growth factors, as genetic studies revealed similar gene expression profiles in PTMC and PTC (Kim *et al.* 2010; Saranac *et al.* 2011). Possibly, these small malignancies induce a locally defined antitumor immune response (Ehlers & Schott 2014). This hypothesis certainly needs investigation in pediatric population.

Studies in adults have found that PTC patients with coexisting Hashimoto's thyroiditis tend to display specific features (Dvorkin *et al.* 2013; Jara *et al.* 2013; Kwon *et al.* 2014; Zhang *et al.* 2014; Iliadou *et al.* 2015; Noureldine & Tufano 2015). They are likely to be young women, with less aggressive disease, less frequent nodal metastases, less likely to develop recurrence, and have a higher survival rate (Dvorkin *et al.* 2013; Jara *et al.* 2013; Kwon *et al.* 2014; Zhang *et al.* 2014; Iliadou *et al.* 2015; Noureldine & Tufano 2015). In children, in line with Iliadou *et al.* (2015) large pediatric study, we have also found that patients with PTC AIT (+) vs. PTC AIT (-) were older, females (75%) dominated and PTC nodules were smaller. Additionally in our study we have found PTMC in 41.6 % of cases of PTC AIT (+) and higher TSH levels, however without an overt hypothyroiditis. The earlier diagnosis of smaller PTC lesions in AIT (+) than in AIT (-) children was possible due to more frequent monitoring of patients with diagnosis of AITD or with AIT who are followed up with repeated US imaging (Iliadou *et al.* 2015).

In our PTC AIT (+) cohort we have also found local and distant metastases in the lymph nodes and in the lungs. Additionally what should be underlined is the fact that in 40% of PTMC AIT (+) metastases in lymph nodes were found including one patient with PTMC of 9 x 8 x 8 mm with metastases found in as many as 13/29 of lymph nodes assessed. Also in PTMC we observed one case of intrathyroidal invasion with multinodularity (both lesions as small as 7 and 2 mm). Therefore, in contrast to adult studies we are convinced that PTC and also PTMC in AIT (+) patients is not less aggressive disease than in AIT (-) pediatric patients (Iliadou *et al.* 2015). In Iliadou *et al.* (2015) pediatric PTC study no better outcome of DTC was observed in regard to the absence or presence of AIT and additionally in patients with AIT and DTC more frequently invasive DTC with intrathyroidal infiltration and familial PTC were found. We are convinced that both in microPTC and macro PTC total thyroidectomy with lymph node verification

should be performed in accordance to current recommendations (Niedziela *et al.* 2016). On the other hand in early detected nodules as small as 11, 10, 7 and 6 mm for the first time we did not find lymph node involvement what had an impact on the further therapy of our patients enabling the escape from ¹³¹I therapy.

A limitation of the present study is a small number of patients. Multi-center transition studies involving both pediatric and adult patients are needed to evaluate disease course and thyroid ultrasound data especially in the light of controversies regarding ultrasound evaluation of AIT patients. According to previous recommendations thyroid ultrasound scan in children with AIT as not changing the treatment, clinical course or outcome, should not be indicated routinely (de Vries *et al.* 2009) and according to current guidelines ultrasound assessment should be performed annually in children with AIT (Niedziela *et al.* 2016). Due to high coincidence of PTC with AIT in children we are positive that all patients with AIT should have thyroid ultrasound repeated at least annually to detect as small PTC as possible, before invasion to lymph nodes starts, thus enabling escape from ¹³¹I therapy, that stands in line with current recommendations (Niedziela *et al.* 2016, Januś *et al.* 2017).

CONCLUSION

Frequent coexistence of PTC and AIT underlines the need of ultrasound monitoring of patients with AIT and referral for FNAB if nodular goiter is detected. Patients with autoimmune thyroiditis – euthyroid with raised aTPO, aTG or TRab autoantibodies present in the serum as well as patients with AITD without overt hypothyroiditis in both cases with normoechogenic thyroid gland on US imaging should be followed up with at least annual US assessment.

The lack of microcalcifications or increased vascularisation in a solid thyroid nodule is not a criterion of disqualifying from FNAB in children. All solid thyroid nodules should be referred for ultrasound verification in a tertiary thyroid department and finally referred for FNAB verification.

In patients with AIT the natural course of PTC and also microPTC is not less aggressive than in patients with PTC AIT (-). As in 40 % of children with microPTC the metastases in lymph nodes were found in all children with PTC (micro and macroPTC) total thyroidectomy with lymph node verifications should be the treatment of choice.

Authors' contribution: Study design: DJ. Study conduct: DJ. Data collection: DJ, AKK, AW, LW, GD. Data analysis: DJ, GD. Data interpretation: DJ, MW, GD, JS. Drafting manuscript: DJ, MW, JS. Revising manuscript content: DJ, MW, JS. Approving final version of manuscript: DJ, MW, JS. DJ takes responsibility for the integrity of the data analysis.

REFERENCES

- 1 Büyükaşık O, Hasdemir AO, Yalçın E, Celep B, Sengül S, Yandakçı K, et al (2011). The association between thyroid malignancy and chronic lymphocytic thyroiditis: should it alter the surgical approach? *Endokrynol Pol.* **62**: 303–308.
- 2 Carson HJ, Castelli MJ, Gattuso P (1996). Incidence of neoplasia in Hashimoto's thyroiditis: a fine-needle aspiration study. *Diagnostic Cytopathology.* **14**: 38–42.
- 3 Cibas ES, Ali SZ (2009). The Bethesda system for reporting thyroid cytopathology. *Thyroid.* **19**: 1159–1165. doi: 10.1089/thy.2009.0274.
- 4 Corrias A, Cassio A, Weber G (2008). Thyroid nodules and cancer in children and adolescents affected by autoimmune thyroiditis. *Archives of Pediatrics and Adolescent Medicine.* **62**: 526–531.
- 5 Dailey ME, Lindsay S, Skahan R (1955). Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. *AMA Archives of Surgery.* **70**: 291–297.
- 6 Danese D, Gardini A, Farsetti A, Sciacchitano S, Andreoli M, Pontecorvi A (1997). Thyroid carcinoma in children and adolescents. *European Journal of Pediatrics.* **156**: 190–194.
- 7 Dvorkin S, Robenshtok E, Hirsch D, Strenov Y, Shimon I, Benbasat CA (2013). Differentiated thyroid cancer is associated with less aggressive disease and better outcome in patients with coexisting Hashimoto's thyroiditis. *J Clin Endocrinol Metab.* **98**: 2409–2414.
- 8 Ehlers M, Schott M (2014). Hashimoto's thyroiditis and papillary thyroid cancer: are they immunologically linked? *Trends in Endocrinology and Metabolism.* **25**: 656–664.
- 9 Grani G, Calvanese A, Carbotta G, D'Alessandri M, Nesca A, Bianchini M, Del Sordo M, Vitale M, Fumarola A (2015). Thyroid autoimmunity and risk of malignancy in thyroid nodules submitted to fine-needle aspiration cytology. *Head Neck.* **37**: 260–4.
- 10 Iliadou PK, Effraimidis G, Konstantinos M, Grigorios P, Mitsakis P, Patakiouta F, Pazaitou-Panayioutou K (2015). Chronic lymphocytic thyroiditis is associated with invasive characteristics of differentiated thyroid carcinoma in children and adolescents. *European Journal of Endocrinology.* **173**: 827–833.
- 11 Ito Y, Ichihara K, Masuoka H, Fukushima M, Inoue H, Kihara M, Tomoda C, Higashiyama T, Takamura Y, Kobayashi K, Miya A, Miyauchi A (2010). Establishment of an intraoperative staging system (iStage) by improving UICC TNM classification system for papillary thyroid carcinoma. *World J Surg.* **34**: 2570–80. doi: 10.1007/s00268-010-0710-2. Erratum in: *World J Surg.* 2011 **35**: 472.
- 12 Jankovic B, Le KT, Hershman JM (2013). Clinical review: Hashimoto's thyroiditis and papillary thyroid carcinoma: is there a correlation? *J Clin Endocrinol Metab.* **98**: 474–482.
- 13 Januś D, Wójcik M, Drabik G, Wyrobek Ł, Starzyk JB (2017). Ultrasound variants of autoimmune thyroiditis in children and adolescents and their clinical implication in relation to papillary thyroid carcinoma development. *J Endocrinol Invest.* Sep 2. doi: 10.1007/s40618-017-0758-z. [Epub ahead of print].
- 14 Jara SM, Carson KA, Pai SI, Agrawal N, Richmon JD, Prescott JD, Dackiw A, Zeiger MA, Bishop JA, Tufano RP. (2013). The relationship between chronic lymphocytic thyroiditis and central neck lymph node metastasis in North American patients with papillary thyroid carcinoma. *Surgery.* **154**: 1272–1280.
- 15 Kim HY, Park WY, Lee KE, Park WS, Chung YS, Cho SJ, Youn YK (2010). Comparative analysis of gene expression profiles of papillary thyroid microcarcinoma and papillary thyroid carcinoma. *J Cancer Res Ther.* **4**: 452–457.
- 16 Kwon JH, Nam ES, Shin HS, Cho SJ, Park HR, Kwon MJ (2014). P2X7 receptor expression in coexistence of papillary thyroid carcinoma with Hashimoto's thyroiditis. *Korean J Pathol.* **48**: 30–35.
- 17 Latrofa F, Ricci D, Grasso L, Vitti P, Masserini L, Basolo F, Ugolini C, Mascia G, Lucacchini A, Pinchera A (2008). Characterization of thyroglobulin epitopes in patients with autoimmune and non-autoimmune thyroid diseases using recombinant human monoclonal thyroglobulin autoantibodies. *J Clin Endocrinol Metab.* **2**: 591–596.
- 18 Niedziela M (2006). Pathogenesis, diagnosis and management of thyroid nodules in children. *Endocrine-Related Cancer.* **13**: 427–453.
- 19 Niedziela M, Flader M, Harasymczuk J, Trejster E, Rabska-Pietrzak B, Bręborowicz D, Kurzawa P, Bręborowicz J (2015). The increased coexistence of thyroid carcinoma (TC) and autoimmune thyroiditis (AIT) in children and adolescents of Greater Poland in years 2001–2015 compared to years 1996–2000. *Endokrynol Pol.* **0215** A76.
- 20 Niedziela M, Handkiewicz-Junak D, Małecka-Tendera E, Czarniecka A, Dedecjus M, Lange D, Kucharska A, Gawlik A, Pomorski L, Włoch J, Baglaj M, Słowińska-Klencka D, Sporny S, Kurzawa P, Kropińska A, Krajewska J, Czepczyński R, Ruchała M, Lewiński A, Jarzab B. (2016). Diagnostics and treatment of differentiated thyroid carcinoma in children – Guidelines of Polish National Societies. *Endokrynol Pol.* **67**: 628–642.
- 21 Noureldine SI, Tufano RP (2015). Association of Hashimoto's thyroiditis and thyroid cancer. *Curr Opin Oncol.* **27**: 21–25.
- 22 O'Groman CS, Hamilton J, Rachmiel M, Gupta A, Ngan BY, Dane-man D (2010). Thyroid cancer in childhood: a retrospective review of childhood course. *Thyroid.* **20**: 375–380.
- 23 Oh CM, Park S, Lee JY, Won YJ, Shin A, Kong HJ, Choi KS, Lee YJ, Chung KW, Jung KW (2014). Increased prevalence of chronic lymphocytic thyroiditis in Korean patients with papillary thyroid cancer. *PLoS One* **9**: e99054.
- 24 Ott RA, Calandra DB, McCall A (1985). The incidence of thyroid carcinoma in patients with Hashimoto's thyroiditis and solitary cold nodules. *Surgery.* **98**: 1202–1206.
- 25 Paparodis R, Imam S, Todorova-Koteva K, Staii A, Jaume JC (2014). Hashimoto's thyroiditis pathology and risk for thyroid cancer. *Thyroid.* **24**: 1107–1114.
- 26 Park S, Jeong JS, Ryu HR, Lee CR, Park JH, Kang SW, Jeong JJ, Nam KH, Chung WY, Park CS (2013). Differentiated thyroid carcinoma of children and adolescents: 27-year experience in the Yonsei University Health System. *Journal of Korean Medical Science.* **28**: 693–699.
- 27 Rebuffat SA, Nguyen B, Robert B, Castex F, Peraldi-Roux S (2008). Antithyroperoxidase antibody-dependent cytotoxicity in autoimmune thyroid disease. *J Clin Endocrinol Metab.* **3**: 929–934.
- 28 Saranac L, Zivanovic S, Bjelakovic B, Stamenkovic H, Novak M, Kamenov B (2011). Why is the thyroid so prone to autoimmune disease? *Horm Res Paediatr.* **3**: 157–165.
- 29 Schäffler A, Palitzsch KD, Seiffarth C, Höhne HM, Riedhammer FJ, Hofstädter F, Schölmerich J, Rüschoff J (1998). Coexistent thyroiditis is associated with lower tumour stage in thyroid carcinoma. *Eur J Clin Invest.* **28**: 838–44.
- 30 Vasileiadis I, Boutzios G, Charitoudis G, Koukouliti E, Karatzas T (2014). Thyroglobulin antibodies could be a potential predictive marker for papillary thyroid carcinoma. *Ann Surg Oncol.* **8**: 2725–2732.
- 31 de Vries L, Bulvik S, Phillip M (2009). Chronic autoimmune thyroiditis in children and adolescents: at presentation and during long-term follow-up. *Arch Dis Child.* **94**: 33–7 doi: 10.1136/adc.2007.134841. Epub 2008 Aug 14.
- 32 Weetman AP (2004). Autoimmune thyroid disease. *Autoimmunity.* **4**: 337–340.
- 33 Zdraveska N, Kocova M (2012). Hashimoto Thyroiditis in Childhood – Review of the Epidemiology, Genetic Susceptibility and Clinical Aspects of the Disease. *Macedonian Journal of Medical Science.* **15**: 336–345.
- 34 Zhang Y, Dai J, Wu T, Yang N, Yin Z (2014). The study of the coexistence of Hashimoto's thyroiditis with papillary thyroid carcinoma. *J Cancer Res Clin Oncol.* **140**: 1021–1026.
- 35 Zois C, Stavrou I, Kalogera C, Svarna E (2003). High prevalence of autoimmune thyroiditis in school children after elimination of iodine deficiency in northwestern Greece. *Thyroid.* **13**: 485–9.